Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)
3.3.2023 16:00:00 EET | Business Wire | Press release
Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and provider workflow software (VizTM HCM) intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. Viz.ai has submitted a de novo request to the U.S. Food and Drug Administration (FDA) for the algorithm as a Software-as-a-Medical-Device (SaMD), and the filing has been accepted by the agency for review.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230303005086/en/
Viz.ai Announces Agreement with Bristol Myers Squibb on Hypertrophic Cardiomyopathy (Graphic: Business Wire)
“HCM is the most common inherited heart disease with an estimated prevalence between 1 in 200 and 1 in 500, and one of the leading causes of sudden cardiac death in people under age 35,” said David Huneycutt, M.D., F.A.C.C., a cardiologist at HCA Healthcare’s TriStar Centennial Medical Center in Nashville, Tenn. and an enterprise-wide cardiovascular physician director. “Since a high percentage of patients remain undiagnosed, it is critical that we find solutions to identify patients with suspected HCM sooner.”
HCM is defined by thickened heart muscle, which can make it harder for the heart to pump blood. It is associated with increased risks of atrial fibrillation, mitral valve disease, and heart failure. HCM is estimated to impact an estimated 750,000 people in the United States and 20 million worldwide.1
“At BMS, we believe that the use of AI to detect key, subtle characteristics in bio signals to aid physicians in the screening, diagnosis, treatment and monitoring of diseases will have a critical and positive impact on patients’ lives,” said Suhas Krishna, Vice President, Head of Digital Health Product Management, Bristol Myers Squibb. “We are excited to continue building momentum in our support of Viz.ai’s research and development program. The speed and quality in which this novel AI algorithm & workflow sequencing product was designed, verified, validated, and submitted by Viz.ai for agency review is testament to the ability to drive rapid and meaningful innovation in healthcare.”
Viz HCM is intended to automatically review routine electrocardiograms (ECGs) from across a health system, identify suspected cases of HCM, and notify the appropriate cardiologist. The physician can then review the ECG in a timely manner and take the appropriate clinical action, including recommending follow-up diagnostic testing in parallel to the standard of care. Viz HCM will be integrated into the Viz.ai Cardio Suite for U.S. hospitals, which is expected to advance cardiac care coordination through a mobile-based electrocardiogram viewer, built with timely AI-powered alerts and communication tools. The Viz.ai Intelligent Care Coordination Platform, which includes Viz.ai Cardio Suite, is adopted by nearly 1,300 hospitals in the U.S. Viz.ai has placed Viz HCM at several hospitals, including select HCA Healthcare facilities, under research agreements to further evaluate the product in clinical practice. The company plans to launch Viz HCM broadly upon FDA clearance.
“Hypertrophic cardiomyopathy can be a devastating disease. The agreement with Bristol Myers Squibb gives us the opportunity to enable underdiagnosed and underserved HCM patients to get the care they need from appropriate providers at the right time,” said Dr. Chris Mansi, CEO at Viz.ai. “Incorporating the new HCM module into the Viz Cardio Suite is expected to enhance detection, expedite care, and empower clinicians and patients.”
For more information on Viz HCM for research, please visit https://www.viz.ai/research/hcm.
*Viz HCM not available for sale. Investigational use only
1 Maron BJ. N Engl J Med. 2018; 379:655-68.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase access to life-saving treatments, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients, informs critical decisions at the point of care, and helps improve outcomes. Backed by real-world clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005086/en/
Contact information
Ariane Lovell
ariane.lovell@finnpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Revolutionizing Performance Measurement: Industry-First Methodology for Testing 5G Network Slices Enabled by Ookla and Ericsson23.2.2026 13:00:00 EET | Press release
Ookla®, a global leader in connectivity intelligence, and Ericsson, a world leader in communications technology, demonstrate an innovative solution allowing users to measure and validate 5G network slicing performance. This collaboration marks a major milestone in the 5G-Advanced era, providing a way to validate the Quality of Experience (QoE) essential for the next generation of mobile applications and use cases. Historically, measuring the performance of an individual network slice from a consumer or enterprise device has been a significant technical challenge. Traditional speed tests measure the default internet connection. Through this collaboration, Ookla and Ericsson developed a methodology that enables the Speedtest app to identify and test specific network slices. This breakthrough demonstrates how Service Level Agreements (SLAs) for differentiated services can finally be verified in real-time by both consumers using the Speedtest app and service providers. Crucially, this puts
Lenovo Unlocks Data Potential with Next Generation of AI-Driven ThinkEdge Solutions23.2.2026 13:00:00 EET | Press release
Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/ ThinkEdge SE10n Gen 2 As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractical. Powered by Intel Core processors with scalable AI options, the fanless rugged lineup features industrial design ideal for 24/7 opera
Ant Group’s Alipay AI Pay and AI Health App AQ Each Surpass 100 Million Users During CNY as AI Adoption Accelerates in China23.2.2026 11:48:00 EET | Press release
As AI adoption gained momentum during the 2026 Chinese New Year, Ant Group announced today that both Alipay AI Pay and its AI health app AQ have each surpassed the 100 million user milestone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223266559/en/ A Chinese consumer paying with Alipay AI payment solution while ordering coffee AI Payment Adoption Accelerates amid CNY AI Shopping Boom From ordering bubble tea and coffee to buying movie tickets, Chinese consumers embraced AI-powered services in everyday scenarios during this year’s holiday, driving a surge in Alipay AI Pay usage. Alipay AI Pay has surpassed 100 million users on February 23, becoming the world’s first AI-native payment product to reach this milestone. This surge highlights the broad commercial adoption of AI-powered payments. During the week of February 5-11, Alipay AI Pay processed over 120 million transactions. Launched in 2025, Alipay AI Pay is an inn
Australian Motoring Service Adds Support for Apple’s Roadside Assistance via Satellite through Infobip23.2.2026 11:43:00 EET | Press release
Global cloud communication platform Infobip supports Apple’s Roadside Assistance via satellite feature through Australian Motoring Service (AMS).* The groundbreaking technology enables drivers with iPhone 14 or later to request help and text with AMS — even in areas without cellular coverage — marking a significant advancement in automotive safety and customer service in Australia. According to the Australian Government, many parts of Australia’s regional and remote areas have no or poor mobile reception, which can make roadside assistance challenging. By leveraging Apple’s Roadside Assistance via satellite on Infobip's Cloud Contact Center solution, AMS provides critical support to stranded motorists in remote locations, including isolated highways, national parks, and mountainous regions. Rebecca Stenhouse, Chief Executive Officer at AMS, said: “At AMS, our priority is ensuring the safety and security of drivers across Australia. With Apple’s Roadside Assistance via satellite and Inf
AOP Health on Rare Diseases: Information. Collaboration. Innovation.23.2.2026 11:00:00 EET | Press release
Between 27 and 36 million1 people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment2. Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223167500/en/ Rare Diseases: Collaboration is key. image: AdobeStock_1308212316 “Working in rare diseases sin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom